A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer. Wang F, Li W, Han G, Xie J, et al. Breast Cancer Res 2025;27:47.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wang F, Li W, Han G, Xie J, et al. A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer. Breast Cancer Res 2025;27:47.
PMID: 40165319